Literature DB >> 26601059

Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease.

Atul F Kamath1, Michael H McGraw1, Craig L Israelite1.   

Abstract

Sickle cell disease is a known risk factor for osteonecrosis of the hip. Necrosis within the femoral head may cause severe pain, functional limitations, and compromise quality of life in this patient population. Early stages of avascular necrosis of the hip may be managed surgically with core decompression with or without autologous bone grafting. Total hip arthroplasty is the mainstay of treatment of advanced stages of the disease in patients who have intractable pain and are medically fit to undergo the procedure. The management of hip pathology in sickle cell disease presents numerous medical and surgical challenges, and the careful perioperative management of patients is mandatory. Although there is an increased risk of medical and surgical complications in patients with sickle cell disease, total hip arthroplasty can provide substantial relief of pain and improvement of function in the appropriately selected patient.

Entities:  

Keywords:  Avascular necrosis; Core decompression; Hip; Orthopedic; Osteonecrosis; Sickle cell disease; Total hip arthroplasty

Year:  2015        PMID: 26601059      PMCID: PMC4644865          DOI: 10.5312/wjo.v6.i10.776

Source DB:  PubMed          Journal:  World J Orthop        ISSN: 2218-5836


  38 in total

1.  [Treatment of early avascular necrosis of femoral head by core decompression combined with autologous bone marrow mesenchymal stem cells transplantation].

Authors:  Tingjie Chang; Kanglai Tang; Xu Tao; Honghui Cao; Hui Li; Qianbo Chen; Lei Chen; Jianbo Zhou; Binghua Zhou; Jianzhong Xu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2010-06

2.  Perioperative complications in patients with sickle cell disease. An orthopedic perspective.

Authors:  M S Garden; R E Grant; S Jebraili
Journal:  Am J Orthop (Belle Mead NJ)       Date:  1996-05

3.  Hip arthroplasty in patients with sickle-cell haemoglobinopathy.

Authors:  M T Acurio; R J Friedman
Journal:  J Bone Joint Surg Br       Date:  1992-05

4.  Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies. Role of cementless components.

Authors:  J M Hickman; P F Lachiewicz
Journal:  J Arthroplasty       Date:  1997-06       Impact factor: 4.757

5.  Total hip arthroplasty in patients who have sickle-cell hemoglobinopathy.

Authors:  A R Bishop; J R Roberson; J R Eckman; L L Fleming
Journal:  J Bone Joint Surg Am       Date:  1988-07       Impact factor: 5.284

6.  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors:  Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

7.  The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Antonios Bilalis; Eleni Plata; Konstantinos Varvagiannis; George Stamatopoulos; Klio Sinopoulou; Aggeliki Balassopoulou; Dimitris Loukopoulos; Evangelos Terpos
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

8.  Total hip arthroplasty in sickle cell hemoglobinopathy.

Authors:  M C Moran; M H Huo; K L Garvin; P M Pellicci; E A Salvati
Journal:  Clin Orthop Relat Res       Date:  1993-09       Impact factor: 4.176

9.  Sickle cell disease as a cause of osteonecrosis of the femoral head.

Authors:  P F Milner; A P Kraus; J I Sebes; L A Sleeper; K A Dukes; S H Embury; R Bellevue; M Koshy; J W Moohr; J Smith
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

10.  Total THA in adult osteonecrosis related to sickle cell disease.

Authors:  Philippe Hernigou; Sebastien Zilber; Paolo Filippini; Gilles Mathieu; Alexandre Poignard; Frederic Galacteros
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

View more
  6 in total

Review 1.  Optimizing management of sickle cell disease in patients undergoing surgery.

Authors:  Charity I Oyedeji; Ian J Welsby
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Hip replacement in femoral head osteonecrosis: current concepts.

Authors:  Michelangelo Scaglione; Luca Fabbri; Fabio Celli; Francesco Casella; Giulio Guido
Journal:  Clin Cases Miner Bone Metab       Date:  2016-04-07

3.  Increased serum protein levels by Yuanshi Shengmai Chenggu Tablet in treatment of avascular osteonecrosis of the femoral head.

Authors:  Jianchun Zeng; Peng Deng; Jie Li; Wenjun Feng; Jinlun Chen; Yirong Zeng
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

4.  Short-Term Outcome and MRI Changes in Three Adult Patients with Sickle Cell Disease and Aseptic Osteonecrosis after Treatment with Hyperbaric Oxygen Therapy: A Preliminary Report.

Authors:  Amr Shier; Mohamed Abdelrazek; Ashraf Soliman; Vincenzo De Sanctis; Ahmed Elsayed; Mohamed Abdulla; Shehab Mohamed; Khadra Yassin; Ilham Bilal; Mohamed Yassin
Journal:  Case Rep Oncol       Date:  2020-04-02

5.  Management of osteonecrosis of the femoral head in children with sickle cell disease: results of conservative and operative treatments at skeletal maturity.

Authors:  C Mallet; A Abitan; C Vidal; L Holvoet; K Mazda; A-L Simon; B Ilharreborde
Journal:  J Child Orthop       Date:  2018-02-01       Impact factor: 1.548

6.  Screening of Serum Protein Markers for Avascular Osteonecrosis of Femoral Head Differentially Expressed after Treatment with Yuanshi Shengmai Chenggu Tablets.

Authors:  Peng Deng; Jianchun Zeng; Jie Li; Wenjun Feng; Jinlun Chen; Yirong Zeng
Journal:  Biomed Res Int       Date:  2018-03-20       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.